evaluation
of
long
term
tobramycin
therapy
in
patients
with
cystic
fibrosis
and
advanced
pulmonary
disease
to
nine
cystic
fibrosis
patients
with
chronic
bronchopulmonary
infection
of
severely
damaged
lungs
invaded
by
pseudomonas
aeruginosa
eleven
courses
of
prolonged
tobramycin
treatment
mg
kg
day
for
four
to
weeks
were
administered
pulmonary
symptoms
improved
and
a
better
quality
of
life
was
achieved
in
all
but
one
patient
objective
parameters
chest
x
ray
pulmonary
function
tests
changed
to
a
lesser
extent
in
only
one
patient
was
pseudomonas
eradicated
from
the
sputum
but
reappeared
after
discontinuation
of
therapy
in
the
rest
of
the
patients
pseudomonas
was
significantly
suppressed
or
replaced
by
other
pathogens
four
patients
showed
rises
of
antibody
titres
to
candida
and
two
to
aspergillus
fumigatus
no
nephrotoxic
side
effects
were
observed
but
vestibular
function
was
reversibly
impaired
in
one
patient
without
corresponding
clinical
symptoms
no
bacterial
resistance
to
tobramycin
was
observed
during
therapy
